Bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3.

Bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3.

Provided herein are compositions and methods for the treatment and prevention of cadherin-11 (CDH11) related diseases. The compositions include CDH11 inhibitors that are formulated for use in combination with chemotherapy and/or immunotherapy, to treat or prevent cancer, fibrosis, and autoimmune diseases.

Provided herein are compositions and methods for the treatment and prevention of cadherin-11 (CDH11) related diseases. The compositions include CDH11 inhibitors that are formulated for use in combination with chemotherapy and/or immunotherapy, to treat or prevent cancer, fibrosis, and autoimmune diseases.

Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

The invention belongs to the technical field of biomedicament, and more specifically relates to an application of compound amino acids in preparation of a medicament for improving sensitivity of bacteria to antibiotics. Experiments have shown that a combination of compound amino acids and antibiotics can improve the sensitivity of bacteria to antibiotics, promote an entry of antibiotics into bacterial cells, significantly increase an intracellular antibiotic content, and improve a bactericidal effect of antibiotics, thereby reducing a survival rate of bacteria, and treating diseases caused by bacterial infection.